Uproleselan
- Generic Name
- Uproleselan
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C60H109N3O27
- CAS Number
- 1983970-12-2
- Unique Ingredient Identifier
- PE952ANF83
- Background
Uproleselan is a novel, specific E-Selectin antagonist under investigation in clinical trial NCT02306291 (Study to Determine Safety, Pharmacokinetics and Efficacy of GMI-1271 in Combination With Chemotherapy in AML).
- Associated Conditions
- -
- Associated Therapies
- -
Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory and That Expresses E-selectin Ligand on the Cell Membrane
- Conditions
- Acute Myeloid Leukemia Post Cytotoxic TherapyRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid LeukemiaRefractory Myelodysplastic SyndromeRecurrent Myelodysplastic SyndromeRefractory Mixed Phenotype Acute LeukemiaDown SyndromeMyelodysplastic Syndrome Post Cytotoxic TherapyRecurrent Mixed Phenotype Acute Leukemia
- Interventions
- Drug: CytarabineDrug: FludarabineDrug: LeucovorinDrug: Triple Intrathecal ChemotherapyDrug: Uproleselan
- First Posted Date
- 2021-12-07
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 22
- Registration Number
- NCT05146739
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
Daunorubicin and Cytarabine With or Without Uproleselan in Treating Older Adult Patients With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: CytarabineDrug: DaunorubicinProcedure: EchocardiographyProcedure: Multigated Acquisition ScanDrug: Uproleselan
- First Posted Date
- 2018-10-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 670
- Registration Number
- NCT03701308
- Locations
- 🇺🇸
Mercy Health - Perrysburg Hospital, Perrysburg, Ohio, United States
🇺🇸University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States
🇺🇸Community Cancer Institute, Clovis, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.